Transatlantique Private Wealth LLC Takes $512,000 Position in Kenvue Inc. $KVUE

Transatlantique Private Wealth LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 29,688 shares of the company’s stock, valued at approximately $512,000.

A number of other hedge funds also recently bought and sold shares of KVUE. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the last quarter. Physician Wealth Advisors Inc. lifted its position in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Elyxium Wealth LLC bought a new stake in Kenvue in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. lifted its position in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares during the last quarter. Finally, Atlantic Union Bankshares Corp lifted its position in Kenvue by 184.1% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock worth $43,000 after buying an additional 1,697 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $16.87 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The business’s 50 day simple moving average is $17.37 and its two-hundred day simple moving average is $17.47. The stock has a market capitalization of $32.38 billion, a P/E ratio of 19.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.54. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 EPS. Analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. Kenvue’s payout ratio is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. UBS Group dropped their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Argus upgraded Kenvue to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.